Citations (82)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (11)
Hanlan Liu, Jayaprakasam Bolleddula, Andrew Nichols, Lei Tang, Zhiyang Zhao & Chandra Prakash. (2020) Metabolism of bioconjugate therapeutics: why, when, and how?. Drug Metabolism Reviews 52:1, pages 66-124.
Read now
Read now
Mira Woitok, Diana Klose, Stefano Di Fiore, Wolfgang Richter, Christoph Stein, Gerrit Gresch, Elena Grieger, Stefan Barth, Rainer Fischer, Katharina Kolberg & Judith Niesen. (2017) Comparison of a mouse and a novel human scFv-SNAP-auristatin F drug conjugate with potent activity against EGFR-overexpressing human solid tumor cells. OncoTargets and Therapy 10, pages 3313-3327.
Read now
Read now
Linlin Jiang, Ming Yang, Xiaoyun Zhang, Shiqi Bao, Li Ma, Dongmei Fan, Yuan Zhou, Dongsheng Xiong & Yongsu Zhen. (2016) A novel antibody–drug conjugate anti-CD19(Fab)-LDM in the treatment of B-cell non-Hodgkin lymphoma xenografts with enhanced anticancer activity. Journal of Drug Targeting 24:1, pages 47-57.
Read now
Read now
Alain Beck, Paul J. Carter, Hans-Peter Gerber, Alexey A. Lugovskoy, Thierry Wurch, Jagath R. Junutula, Roland E Kontermann & Robert Mabry. (2013) 8th Annual European Antibody Congress 2012. mAbs 5:3, pages 339-357.
Read now
Read now
Manuel Simon, Nikolas Stefan, Andreas Plückthun & Uwe Zangemeister-Wittke. (2013) Epithelial cell adhesion molecule-targeted drug delivery for cancer therapy. Expert Opinion on Drug Delivery 10:4, pages 451-468.
Read now
Read now
Divaya Bhutani & Ulka N Vaishampayan. (2013) Monoclonal antibodies in oncology therapeutics: present and future indications. Expert Opinion on Biological Therapy 13:2, pages 269-282.
Read now
Read now
Alain Beck, John Lambert, Michael Sun & Kedan Lin. (2012) Fourth World Antibody-Drug Conjugate Summit. mAbs 4:6, pages 637-647.
Read now
Read now
John R Adair, Philip W Howard, John A Hartley, David G Williams & Kerry A Chester. (2012) Antibody–drug conjugates – a perfect synergy. Expert Opinion on Biological Therapy 12:9, pages 1191-1206.
Read now
Read now
David M Goldenberg & Robert M Sharkey. (2012) Using antibodies to target cancer therapeutics. Expert Opinion on Biological Therapy 12:9, pages 1173-1190.
Read now
Read now
Serengulam V Govindan & David M Goldenberg. (2012) Designing immunoconjugates for cancer therapy. Expert Opinion on Biological Therapy 12:7, pages 873-890.
Read now
Read now
Alexey A. Lugovskoy, Janice M. Reichert & Alain Beck. (2012) 7th Annual European Antibody Congress 2011. mAbs 4:2, pages 134-152.
Read now
Read now
Articles from other publishers (71)
Rajesh Pradhan, Meghna Pandey, Siddhanth Hejmady, Rajeev Taliyan, Gautam Singhvi, Sunil K. Dubey & Sachin Dubey. 2022. Targeted Drug Delivery. Targeted Drug Delivery
127
154
.
Yue Wei, Si Wu, Zhenqi Liu, Jingsheng Niu, Ya Zhou, Jinsong Ren & Xiaogang Qu. (2022) Tumor associated macrophages reprogrammed by targeted bifunctional bioorthogonal nanozymes for enhanced tumor immunotherapy. Materials Today 56, pages 16-28.
Crossref
Crossref
Utsab Debnath, Saroj Verma, Jeevan Patra & Sudip Kumar Mandal. (2022) A review on recent synthetic routes and computational approaches for antibody drug conjugation developments used in anti-cancer therapy. Journal of Molecular Structure 1256, pages 132524.
Crossref
Crossref
Jung Hoon Kim & In Ho Chang. (2022) A novel strategy for treatment of bladder cancer: Antibody-drug conjugates. Investigative and Clinical Urology 63:4, pages 373.
Crossref
Crossref
Yiming Jin, Megan A. Schladetsch, Xueting Huang, Marcy J. Balunas & Andrew J. Wiemer. (2022) Stepping forward in antibody-drug conjugate development. Pharmacology & Therapeutics 229, pages 107917.
Crossref
Crossref
Xinyue Hu, Hailun Jiang, Weiqi Bai, Xiujun Liu, Qingfang Miao, Linlin Wang, Jie Jin, Along Cui, Rui Liu & Zhuorong Li. (2021) Synthesis, characterization, and targeted chemotherapy of SCT200-linker-monomethyl auristatin E conjugates. European Journal of Medicinal Chemistry 216, pages 113297.
Crossref
Crossref
Qiang Wang, Jiankun Guan, Jiangling Wan & Zifu Li. (2020) Disulfide based prodrugs for cancer therapy. RSC Advances 10:41, pages 24397-24409.
Crossref
Crossref
Lee S. Rosen, Robert Wesolowski, Raffaele Baffa, Kai-Hsin Liao, Steven Y. Hua, Brenda L. Gibson, Steven Pirie-Shepherd & Anthony W. Tolcher. (2019) A phase I, dose-escalation study of PF-06650808, an anti-Notch3 antibody–drug conjugate, in patients with breast cancer and other advanced solid tumors. Investigational New Drugs 38:1, pages 120-130.
Crossref
Crossref
Nooshafarin Amani, Farid Abedin Dorkoosh & Hamid Mobedi. (2020) ADCs, as Novel Revolutionary Weapons for Providing a Step Forward in Targeted Therapy of Malignancies. Current Drug Delivery 17:1, pages 23-51.
Crossref
Crossref
Puregmaa Khongorzul, Cai Jia Ling, Farhan Ullah Khan, Awais Ullah Ihsan & Juan Zhang. (2020) Antibody–Drug Conjugates: A Comprehensive Review. Molecular Cancer Research 18:1, pages 3-19.
Crossref
Crossref
Sajad Yaghoubi, Mohammad Hossein Karimi, Majid Lotfinia, Tohid Gharibi, Motahare Mahi‐Birjand, Esmaeil Kavi, Fahimeh Hosseini, Koushan Sineh Sepehr, Mehrdad Khatami, Nader Bagheri & Meghdad Abdollahpour‐Alitappeh. (2019) Potential drugs used in the antibody–drug conjugate (ADC) architecture for cancer therapy. Journal of Cellular Physiology 235:1, pages 31-64.
Crossref
Crossref
Ignacio Garrido-Laguna, Ian Krop, Howard A. BurrisIIIIII, Erika Hamilton, Fadi Braiteh, Amy M. Weise, Maysa Abu-Khalaf, Theresa L. Werner, Steven Pirie-Shepherd, Christopher J. Zopf, Mani Lakshminarayanan, Jaymes S. Holland, Raffaele Baffa & David S. Hong. (2019) First-in-human, phase I study of PF-06647263, an anti-EFNA4 calicheamicin antibody-drug conjugate, in patients with advanced solid tumors. International Journal of Cancer 145:7, pages 1798-1808.
Crossref
Crossref
Si Mou, Yue Huang & Anton Rosenbaum. (2018) ADME Considerations and Bioanalytical Strategies for Pharmacokinetic Assessments of Antibody-Drug Conjugates. Antibodies 7:4, pages 41.
Crossref
Crossref
Laurel M. Schunselaar, Kim Monkhorst, Vincent van der Noort, Ruud Wijdeven, Dennis Peters, Wilbert Zwart, Jacques Neefjes & Paul Baas. (2018) Trophoblast Glycoprotein is Associated With a Favorable Outcome for Mesothelioma and a Target for Antibody Drug Conjugates. Journal of Thoracic Oncology 13:10, pages 1577-1587.
Crossref
Crossref
Hadi Nasiri, Zahra Valedkarimi, Leili Aghebati‐Maleki & Jafar Majidi. (2018) Antibody‐drug conjugates: Promising and efficient tools for targeted cancer therapy. Journal of Cellular Physiology 233:9, pages 6441-6457.
Crossref
Crossref
Raffaella Rossin, Ron M. Versteegen, Jeremy Wu, Alisher Khasanov, Hans J. Wessels, Erik J. Steenbergen, Wolter ten Hoeve, Henk M. Janssen, Arthur H. A. M. van Onzen, Peter J. Hudson & Marc S. Robillard. (2018) Chemically triggered drug release from an antibody-drug conjugate leads to potent antitumour activity in mice. Nature Communications 9:1.
Crossref
Crossref
Nirnoy Dan, Saini Setua, Vivek Kashyap, Sheema Khan, Meena Jaggi, Murali Yallapu & Subhash Chauhan. (2018) Antibody-Drug Conjugates for Cancer Therapy: Chemistry to Clinical Implications. Pharmaceuticals 11:2, pages 32.
Crossref
Crossref
Alexander V. LyubimovEugenia Kraynov & Steven W. Martin. 2011. Encyclopedia of Drug Metabolism and Interactions. Encyclopedia of Drug Metabolism and Interactions
1
22
.
Yanming Wang, Shiyong Fan, Wu Zhong, Xinbo Zhou & Song Li. (2017) Development and Properties of Valine-Alanine based Antibody-Drug Conjugates with Monomethyl Auristatin E as the Potent Payload. International Journal of Molecular Sciences 18:9, pages 1860.
Crossref
Crossref
Jae Wook Kim. (2017) Antibody-Drug Conjugates in Head and Neck Cancer. Korean Journal of Otorhinolaryngology-Head and Neck Surgery 60:7, pages 331-335.
Crossref
Crossref
Yongjun Xue, Priya Sriraman, Matthew V. Myers, Xiaomin Wang, Jian Chen, Brian Melo, Martha Vallejo, Stephen E. Maxwell & Sekhar Surapaneni. 2017. Protein Analysis using Mass Spectrometry. Protein Analysis using Mass Spectrometry
183
201
.
Geoffrey I. Shapiro, Ulka N. Vaishampayan, Patricia LoRusso, Jeremy Barton, Steven Hua, Steven D. Reich, Ronald Shazer, Carrie T. Taylor, Dawei Xuan & Hossein Borghaei. (2017) First-in-human trial of an anti-5T4 antibody-monomethylauristatin conjugate, PF-06263507, in patients with advanced solid tumors. Investigational New Drugs 35:3, pages 315-323.
Crossref
Crossref
Jörg Willuda, Lars Linden, Hans-Georg Lerchen, Charlotte Kopitz, Beatrix Stelte-Ludwig, Carol Pena, Claudia Lange, Sven Golfier, Christoph Kneip, Patricia E. Carrigan, Kirk Mclean, Joachim Schuhmacher, Oliver von Ahsen, Jörg Müller, Frank Dittmer, Rudolf Beier, Sherif El Sheikh, Jan Tebbe, Gabriele Leder, Heiner Apeler, Rolf Jautelat, Karl Ziegelbauer & Bertolt Kreft. (2017) Preclinical Antitumor Efficacy of BAY 1129980—a Novel Auristatin-Based Anti-C4.4A (LYPD3) Antibody–Drug Conjugate for the Treatment of Non–Small Cell Lung Cancer. Molecular Cancer Therapeutics 16:5, pages 893-904.
Crossref
Crossref
Amit Kumar, Jason White, R. James Christie, Nazzareno Dimasi & Changshou Gao. 2017. Platform Technologies in Drug Discovery and Validation. Platform Technologies in Drug Discovery and Validation
441
480
.
Hans-Peter Gerber, Marc Damelin & Puja Sapra. 2017. Next Generation Antibody Drug Conjugates (ADCs) and Immunotoxins. Next Generation Antibody Drug Conjugates (ADCs) and Immunotoxins
69
84
.
Frank Loganzo, Matthew Sung & Hans-Peter Gerber. (2016) Mechanisms of Resistance to Antibody–Drug Conjugates. Molecular Cancer Therapeutics 15:12, pages 2825-2834.
Crossref
Crossref
Xinyu Liu & Weiping Gao. 2016. Biomedical Nanomaterials. Biomedical Nanomaterials
149
176
.
Raffaella Rossin, Sander M. J. van Duijnhoven, Wolter ten Hoeve, Henk M. Janssen, Laurens H. J. Kleijn, Freek J. M. Hoeben, Ron M. Versteegen & Marc S. Robillard. (2016) Triggered Drug Release from an Antibody–Drug Conjugate Using Fast “Click-to-Release” Chemistry in Mice. Bioconjugate Chemistry 27:7, pages 1697-1706.
Crossref
Crossref
Nils Griebenow, Alicia M. Dilmaç, Simone Greven & Stefan Bräse. (2016) Site-Specific Conjugation of Peptides and Proteins via Rebridging of Disulfide Bonds Using the Thiol–Yne Coupling Reaction. Bioconjugate Chemistry 27:4, pages 911-917.
Crossref
Crossref
Jun Lu, Feng Jiang, Aiping Lu & Ge Zhang. (2016) Linkers Having a Crucial Role in Antibody–Drug Conjugates. International Journal of Molecular Sciences 17:4, pages 561.
Crossref
Crossref
E. Kraynov, A. V. Kamath, M. Walles, E. Tarcsa, A. Deslandes, R. A. Iyer, A. Datta-Mannan, P. Sriraman, M. Bairlein, J. J. Yang, M. Barfield, G. Xiao, E. Escandon, W. Wang, D. A. Rock, N. V. Chemuturi & D. J. Moore. (2015) Current Approaches for Absorption, Distribution, Metabolism, and Excretion Characterization of Antibody-Drug Conjugates: An Industry White Paper. Drug Metabolism and Disposition 44:5, pages 617-623.
Crossref
Crossref
Nikolaos Diamantis & Udai Banerji. (2016) Antibody-drug conjugates—an emerging class of cancer treatment. British Journal of Cancer 114:4, pages 362-367.
Crossref
Crossref
Sylvain A. Jacques, Geoffray Leriche, Michel Mosser, Marc Nothisen, Christian D. Muller, Jean-Serge Remy & Alain Wagner. (2016) From solution to in-cell study of the chemical reactivity of acid sensitive functional groups: a rational approach towards improved cleavable linkers for biospecific endosomal release. Organic & Biomolecular Chemistry 14:21, pages 4794-4803.
Crossref
Crossref
Marc Damelin, Wenyan Zhong, Jeremy Myers & Puja Sapra. (2015) Evolving Strategies for Target Selection for Antibody-Drug Conjugates. Pharmaceutical Research 32:11, pages 3494-3507.
Crossref
Crossref
Marc Damelin, Alexander Bankovich, Albert Park, Jorge Aguilar, Wade Anderson, Marianne Santaguida, Monette Aujay, Sarah Fong, Kiran Khandke, Virginia Pulito, Elana Ernstoff, Paul Escarpe, Jeffrey Bernstein, Marybeth Pysz, Wenyan Zhong, Erik Upeslacis, Judy Lucas, Justin Lucas, Timothy Nichols, Kathryn Loving, Orit Foord, Johannes Hampl, Robert Stull, Frank Barletta, Hadi Falahatpisheh, Puja Sapra, Hans-Peter Gerber & Scott J. Dylla. (2015) Anti-EFNA4 Calicheamicin Conjugates Effectively Target Triple-Negative Breast and Ovarian Tumor-Initiating Cells to Result in Sustained Tumor Regressions. Clinical Cancer Research 21:18, pages 4165-4173.
Crossref
Crossref
Geoffray Leriche, Marc Nothisen, Nadège Baumlin, Christian D. Muller, Dominique Bagnard, Jean-Serge Remy, Sylvain A. Jacques & Alain Wagner. (2015) Spiro Diorthoester (SpiDo), a Human Plasma Stable Acid-Sensitive Cleavable Linker for Lysosomal Release. Bioconjugate Chemistry 26:8, pages 1461-1465.
Crossref
Crossref
Patrick Dennler, Eliane Fischer & Roger Schibli. (2015) Antibody Conjugates: From Heterogeneous Populations to Defined Reagents. Antibodies 4:3, pages 197-224.
Crossref
Crossref
George Hu, Mauricio Leal, Qingcong Lin, Timothy Affolter, Puja Sapra, Brian Bates & Marc Damelin. (2014) Phenotype of TPBG Gene Replacement in the Mouse and Impact on the Pharmacokinetics of an Antibody–Drug Conjugate. Molecular Pharmaceutics 12:6, pages 1730-1737.
Crossref
Crossref
Antoine Maruani, Mark E.B. Smith, Enrique Miranda, Kerry A. Chester, Vijay Chudasama & Stephen Caddick. (2015) A plug-and-play approach to antibody-based therapeutics via a chemoselective dual click strategy. Nature Communications 6:1.
Crossref
Crossref
Frank Loganzo, Xingzhi Tan, Matthew Sung, Guixian Jin, Jeremy S. Myers, Eugene Melamud, Fang Wang, Veronica Diesl, Maximillian T. Follettie, Sylvia Musto, My-Hanh Lam, William Hu, Manoj B. Charati, Kiran Khandke, Kenny Sung Kyoo Kim, Mike Cinque, Judy Lucas, Edmund Graziani, Andreas Maderna, Christopher J. O'Donnell, Kim T. Arndt & Hans-Peter Gerber. (2015) Tumor Cells Chronically Treated with a Trastuzumab–Maytansinoid Antibody–Drug Conjugate Develop Varied Resistance Mechanisms but Respond to Alternate Treatments. Molecular Cancer Therapeutics 14:4, pages 952-963.
Crossref
Crossref
Gary WalshGary Walsh. 2015. Proteins. Proteins
205
231
.
Debmalya Bhunia, Rajdeep Chowdhury, Kankan Bhattacharyya & Surajit Ghosh. (2015) Fluorescence fluctuation of an antigen–antibody complex: circular dichroism, FCS and smFRET of enhanced GFP and its antibody. Physical Chemistry Chemical Physics 17:38, pages 25250-25259.
Crossref
Crossref
João P. M. Nunes, Maurício Morais, Vessela Vassileva, Eifion Robinson, Vineeth S. Rajkumar, Mark E. B. Smith, R. Barbara Pedley, Stephen Caddick, James R. Baker & Vijay Chudasama. (2015) Functional native disulfide bridging enables delivery of a potent, stable and targeted antibody–drug conjugate (ADC). Chemical Communications 51:53, pages 10624-10627.
Crossref
Crossref
LeeRon Shefet-Carasso & Itai Benhar. (2015) Antibody-targeted drugs and drug resistance—Challenges and solutions. Drug Resistance Updates 18, pages 36-46.
Crossref
Crossref
Jennica L. Zaro, Jeffery Wang & Wei-Chiang Shen. 2015. Antibody-Drug Conjugates. Antibody-Drug Conjugates
235
250
.
Thomas H. Pillow, Janet Tien, Kathryn L. Parsons-Reponte, Sunil Bhakta, Hao Li, Leanna R. Staben, Guangmin Li, Josefa Chuh, Aimee Fourie-O’Donohue, Martine Darwish, Victor Yip, Luna Liu, Douglas D. Leipold, Dian Su, Elmer Wu, Susan D. Spencer, Ben-Quan Shen, Keyang Xu, Katherine R. Kozak, Helga Raab, Richard Vandlen, Gail D. Lewis Phillips, Richard H. Scheller, Paul Polakis, Mark X. Sliwkowski, John A. Flygare & Jagath R. Junutula. (2014) Site-Specific Trastuzumab Maytansinoid Antibody–Drug Conjugates with Improved Therapeutic Activity through Linker and Antibody Engineering. Journal of Medicinal Chemistry 57:19, pages 7890-7899.
Crossref
Crossref
Heidi L. Perez, Pina M. Cardarelli, Shrikant Deshpande, Sanjeev Gangwar, Gretchen M. Schroeder, Gregory D. Vite & Robert M. Borzilleri. (2014) Antibody–drug conjugates: current status and future directions. Drug Discovery Today 19:7, pages 869-881.
Crossref
Crossref
Patrick Dennler, Aristeidis Chiotellis, Eliane Fischer, Delphine Brégeon, Christian Belmant, Laurent Gauthier, Florence Lhospice, François Romagne & Roger Schibli. (2014) Transglutaminase-Based Chemo-Enzymatic Conjugation Approach Yields Homogeneous Antibody–Drug Conjugates. Bioconjugate Chemistry 25:3, pages 569-578.
Crossref
Crossref
Feng TianYingchun LuAnthony ManibusanAaron SellersHon TranYing SunTrung PhuongRichard BarnettBrad HehliFrank SongMichael J. DeGuzman, Semsi Ensari, Jason K. PinkstaffLorraine M. SullivanSandra L. BirocHo ChoPeter G. SchultzJohn DiJoseph, Maureen Dougher, Dangshe Ma, Russell Dushin, Mauricio LealLioudmila Tchistiakova, Eric Feyfant, Hans-Peter Gerber & Puja Sapra. (2014) A general approach to site-specific antibody drug conjugates. Proceedings of the National Academy of Sciences 111:5, pages 1766-1771.
Crossref
Crossref
Azher HussainBoris Gorovits, Mauricio Leal & Eric Fluhler. (2014)
PK of immunoconjugate anticancer agent CMD-193 in rats: ligand-binding assay approach to determine
in vivo
immunoconjugate stability
. Bioanalysis 6:1, pages 21-32.
Crossref
Crossref
John A. Hartley. 2014. Cancer Drug Design and Discovery. Cancer Drug Design and Discovery
479
490
.
R.M. Garbaccio. 2014. Comprehensive Organic Synthesis II. Comprehensive Organic Synthesis II
438
462
.
Kewal K. JainKewal K. Jain. 2014. Applications of Biotechnology in Oncology. Applications of Biotechnology in Oncology
371
391
.
Monika Farys, Claire L. Ginn, George O. Badescu, Karolina Peciak, Estera M. Pawlisz, Hanieh Khalili & Steve J. Brocchini. 2010. Pharmaceutical Sciences Encyclopedia. Pharmaceutical Sciences Encyclopedia
1
52
.
Liangbiao George Hu & David W. Clarke. 2010. Pharmaceutical Sciences Encyclopedia. Pharmaceutical Sciences Encyclopedia
1
26
.
Manuel Simon, Raphael Frey, Uwe Zangemeister-Wittke & Andreas Plückthun. (2013) Orthogonal Assembly of a Designed Ankyrin Repeat Protein–Cytotoxin Conjugate with a Clickable Serum Albumin Module for Half-Life Extension. Bioconjugate Chemistry 24:11, pages 1955-1966.
Crossref
Crossref
Nahor Haddish-Berhane, Dhaval K. Shah, Dangshe Ma, Mauricio Leal, Hans-Peter Gerber, Puja Sapra, Hugh A. Barton & Alison M. Betts. (2013) On translation of antibody drug conjugates efficacy from mouse experimental tumors to the clinic: a PK/PD approach. Journal of Pharmacokinetics and Pharmacodynamics 40:5, pages 557-571.
Crossref
Crossref
Nicholas J. Boylan, Wen Zhou, Robert J. Proos, Thomas J. Tolbert, Janet L. Wolfe & Jennifer S. Laurence. (2013) Conjugation Site Heterogeneity Causes Variable Electrostatic Properties in Fc Conjugates. Bioconjugate Chemistry 24:6, pages 1008-1016.
Crossref
Crossref
Serengulam V. Govindan, Thomas M. Cardillo, Robert M. Sharkey, Fatma Tat, David V. Gold & David M. Goldenberg. (2013) Milatuzumab–SN-38 Conjugates for the Treatment of CD74+ Cancers. Molecular Cancer Therapeutics 12:6, pages 968-978.
Crossref
Crossref
Pamela Trail. (2013) Antibody Drug Conjugates as Cancer Therapeutics. Antibodies 2:4, pages 113-129.
Crossref
Crossref
Puja Sapra, Marc Damelin, John DiJoseph, Kimberly Marquette, Kenneth G. Geles, Jonathon Golas, Maureen Dougher, Bitha Narayanan, Andreas Giannakou, Kiran Khandke, Russell Dushin, Elana Ernstoff, Judy Lucas, Mauricio Leal, George Hu, Christopher J. O'Donnell, Lioudmila Tchistiakova, Robert T. Abraham & Hans-Peter Gerber. (2013) Long-term Tumor Regression Induced by an Antibody–Drug Conjugate That Targets 5T4, an Oncofetal Antigen Expressed on Tumor-Initiating Cells. Molecular Cancer Therapeutics 12:1, pages 38-47.
Crossref
Crossref
John A. Flygare, Thomas H. Pillow & Paul Aristoff. (2013) Antibody-Drug Conjugates for the Treatment of Cancer. Chemical Biology & Drug Design 81:1, pages 113-121.
Crossref
Crossref
Hans-Peter Gerber, Frank E. Koehn & Robert T. Abraham. (2013) The antibody-drug conjugate: an enabling modality for natural product-based cancer therapeutics. Natural Product Reports 30:5, pages 625.
Crossref
Crossref
Lourdes Castañeda, Antoine Maruani, Felix F. Schumacher, Enrique Miranda, Vijay Chudasama, Kerry A. Chester, James R. Baker, Mark E. B. Smith & Stephen Caddick. (2013) Acid-cleavable thiomaleamic acid linker for homogeneous antibody–drug conjugation. Chemical Communications 49:74, pages 8187.
Crossref
Crossref
Frank E. Koehn. 2013. Natural Products and Cancer Drug Discovery. Natural Products and Cancer Drug Discovery
97
119
.
Nikolett Mihala & Ferenc Hudecz. 2012. Amino Acids, Peptides and Proteins. Amino Acids, Peptides and Proteins
1
39
.
Lan N. Le, Jamie M. R. Moore, Jun Ouyang, Xiaoying Chen, Mary D. H. Nguyen & William J. Galush. (2012) Profiling Antibody Drug Conjugate Positional Isomers: A System-of-Equations Approach. Analytical Chemistry 84:17, pages 7479-7486.
Crossref
Crossref
Janice M. Reichert & Eugen Dhimolea. (2012) The future of antibodies as cancer drugs. Drug Discovery Today 17:17-18, pages 954-963.
Crossref
Crossref
Sara Rosati, Natalie J. Thompson, Arjan Barendregt, Linda J. A. Hendriks, Alexander B. H. Bakker, John de Kruif, Mark Throsby, Esther van Duijn & Albert J. R. Heck. (2012) Qualitative and Semiquantitative Analysis of Composite Mixtures of Antibodies by Native Mass Spectrometry. Analytical Chemistry 84:16, pages 7227-7232.
Crossref
Crossref
Youngshang Pak, Yujian Zhang, Ira Pastan & Byungkook Lee. (2012) Antigen Shedding May Improve Efficiencies for Delivery of Antibody-Based Anticancer Agents in Solid Tumors. Cancer Research 72:13, pages 3143-3152.
Crossref
Crossref
Frank E. Koehn. (2012) Biosynthetic medicinal chemistry of natural product drugs. MedChemComm 3:8, pages 854.
Crossref
Crossref